The impact of Demodex blepharitis on patient symptoms and daily life.

Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted in multiple visits to eye care providers, Demodex blepharitis remained underdiagnosed or misdiagnosed. This study aimed to evaluate the effect of Demodex blepharitis on patients' daily activities and well-being. This prospective, multicenter, observational study recruited 524 patients with Demodex blepharitis from 20 U.S. ophthalmology and optometry practices. Demodex blepharitis was diagnosed based on the presence of the following clinical manifestations in at least one eye: >10 collarettes on the upper lashes, at least mild lid margin erythema of the upper eyelid, and mite density of ≥1.0 mite/lash (upper and lower combined). Patients were asked to complete a questionnaire related to their symptoms, daily activities, and management approaches. The proportion of patients who experienced blepharitis symptoms for ≥2 years was 67.8%, and for ≥4 years, it was 46.5%. The three most bothersome symptoms ranked were "itchy eyes," "dry eyes," and "foreign body sensation." Overall, 77.4% of patients reported that Demodex blepharitis negatively affected their daily life. One-third (32.3%) of patients had visited a doctor for blepharitis at least two times, including 19.6% who visited at least four times. Despite having clinical manifestations of Demodex blepharitis confirmed by an eye care provider, 58.7% had never been diagnosed with blepharitis. Commonly used management approaches were artificial tears, warm compresses, and lid wipes. Among those who discontinued their regimen, 45.9% had discontinued because of either tolerability issues or lack of effectiveness. Among contact lens wearers, 64.3% of the patients either were uncomfortable wearing contact lenses or experienced vision changes "sometimes" or "frequently." Demodex blepharitis results in a significant negative impact on daily activities, creating a psychosocial and symptomatic burden on patients.

Informations de copyright

Copyright © 2024 American Academy of Optometry.

Déclaration de conflit d'intérêts

Conflict of Interest Disclosure: MH and SNB are employees of Tarsus Pharmaceuticals. PK has also received consulting fees from Tarsus Pharmaceuticals. PK and WEW are equity stakeholders in Tarsus Pharmaceuticals. EY, LMP, MB, and PV have received personal or consulting fees from Tarsus Pharmaceuticals. EY serves on the board of directors of Tarsus Pharmaceuticals. AP, BS, GJB, and JM do not have any conflicts of interest to disclose related to the content of this article.